BRAF<sup>V600E</sup>, which is the most frequent mutation observed in CM patients, usually increases HIF-α signaling not only in hypoxia, but also in normoxic CM cells, enabling HIF-1α and HIF-2α to continuously activate downstream molecular pathways. Here, HIF1A is linked to cutaneous mastocytosis.